Sonoma Pharmaceuticals, Inc. (SNOA)
NASDAQ: SNOA · Real-Time Price · USD
4.000
+0.170 (4.44%)
At close: Oct 29, 2025, 4:00 PM EDT
3.918
-0.082 (-2.04%)
After-hours: Oct 29, 2025, 5:03 PM EDT
Sonoma Pharmaceuticals Revenue
Sonoma Pharmaceuticals had revenue of $4.01M in the quarter ending June 30, 2025, with 18.40% growth. This brings the company's revenue in the last twelve months to $14.91M, up 17.43% year-over-year. In the fiscal year ending March 31, 2025, Sonoma Pharmaceuticals had annual revenue of $14.29M with 12.19% growth.
Revenue (ttm)
$14.91M
Revenue Growth
+17.43%
P/S Ratio
0.37
Revenue / Employee
$1,864,000
Employees
8
Market Cap
6.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 14.29M | 1.55M | 12.19% |
| Mar 31, 2024 | 12.74M | -537.00K | -4.05% |
| Mar 31, 2023 | 13.27M | 644.00K | 5.10% |
| Mar 31, 2022 | 12.63M | -6.00M | -32.21% |
| Mar 31, 2021 | 18.63M | 701.00K | 3.91% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SNOA News
- 15 days ago - Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals - Accesswire
- 22 days ago - Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA - Accesswire
- 4 weeks ago - Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - Accesswire
- 2 months ago - National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced - Accesswire
- 2 months ago - Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains - Accesswire
- 2 months ago - Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results - Accesswire
- 4 months ago - Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results - Accesswire
- 6 months ago - Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain - Accesswire